RT Journal Article
SR Electronic
T1 Harnessing non-standard nucleic acids for highly sensitive icosaplex (20-plex) detection of microbial threats
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.09.24313328
DO 10.1101/2024.09.09.24313328
A1 Kawabe, Hinako
A1 Manfio, Luran
A1 Pena, Sebastian Magana
A1 Zhou, Nicolette A.
A1 Bradley, Kevin M.
A1 Chen, Cen
A1 McLendon, Chris
A1 Benner, Steven A.
A1 Levy, Karen
A1 Yang, Zunyi
A1 Marchand, Jorge A.
A1 Fuhrmeister, Erica R.
YR 2024
UL http://medrxiv.org/content/early/2024/09/10/2024.09.09.24313328.abstract
AB Environmental surveillance and clinical diagnostics heavily rely on the polymerase chain reaction (PCR) for target detection. A growing list of microbial threats warrants new PCR-based detection methods that are highly sensitive, specific, and multiplexable. Here, we introduce a PCR-based icosaplex (20-plex) assay for detecting 18 enteropathogen and two antimicrobial resistance genes. This multiplexed PCR assay leverages the self-avoiding molecular recognition system (SAMRS) to avoid primer dimer formation, the artificially expanded genetic information system (AEGIS) for amplification specificity, and next-generation sequencing for amplicon identification. We benchmarked this assay using a low-cost, portable sequencing platform (Oxford Nanopore) on wastewater, soil, and human stool samples. Using parallelized multi-target TaqMan Array Cards (TAC) to benchmark performance of the 20-plex assay, there was 74% agreement on positive calls and 97% agreement on negative calls. Additionally, we show how sequencing information from the 20-plex can be used to further classify allelic variants of genes and distinguish sub-species. The strategy presented offers sensitive, affordable, and robust multiplex detection that can be used to support efforts in wastewater-based epidemiology, environmental monitoring, and human/animal diagnostics.Competing Interest StatementS.A.B and Z.Y. own the intellectual property of AEGIS and SAMRS. Many AEGIS and SAMRS components are commercially available from Firebird Biomolecular Sciences, LLC (www.firebirdbio.com, Email: support@firebirdbio.com). The remaining authors declare no competing interests.Funding StatementLM, SMP, KMB, CC, SAB, and ZY were supported by the LRE Diagnostics grant 1R01AI135146-01A1. NAZ and KL were supported by R01AI137679. Laboratory infrastructure and hardware used for this study was supported by the University of Washington Interdisciplinary Center for Exposures, Diseases, Genomics, and Environment funded by the NIEHS (P30ES007033). JM and HK were supported by University of Washington Royalty Research Fund (RRF).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:10 human stool samples were provided from ECoMiD. The ECoMiD study protocol was approved by the institutional review boards of the University of Washington (UW; IRB STUDY00014270), Emory University (IRB00101202), and the Universidad San Francisco de Quito (2018.022M). The study protocol was also reviewed and approved by the Ministry of Health of Ecuador (MSPCURI000253.4).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAssay results summary (number of mapped reads and TAC Ct values) are provided in a Supplementary data file upon publication in a peer reviewed journal. The demultiplexed nanopore sequencing basecalls (FASTQ) for each sample analyzed in this work have been deposited in the sequence reads archive (SRA) under Bioproject PRJNA1150247.The demultiplexed nanopore sequencing basecalls (FASTQ) for each sample analyzed in this work have been deposited in the sequence reads archive (SRA) under Bioproject PRJNA1150247 (Table S9).